98%
921
2 minutes
20
Purpose: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control.
Methods: Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS measures.
Results: On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24% of CYP2D6-guided versus 0% of usual care participants reported ≥30% (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540).
Conclusion: These data support the potential benefits of CYP2D6-guided pain management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650382 | PMC |
http://dx.doi.org/10.1038/s41436-018-0431-8 | DOI Listing |
J Med Internet Res
September 2025
School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Republic of Korea.
Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.
Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.
J Eval Clin Pract
September 2025
Pediatric Allergy and Immunology Department, Akdeniz University Hospital, Akdeniz University, Antalya, Türkiye.
Aims And Objectives: To evaluate the efficacy of YoungAsthma, a nurse-led, web-based mHealth intervention on asthma control and self-efficacy among adolescents with asthma utilizing decision tree analysis.
Background: Asthma is a prevalent chronic condition in pediatric populations, necessitating sustained management for optimal disease control.
Design: A randomized controlled clinical trial.
Dan Med J
August 2025
Department of Clinical Medicine, Aarhus University.
Introduction: Reverse total shoulder arthroplasty is a well-established treatment for patients with rotator cuff tear arthropathy. The outcome after reverse total shoulder arthroplasty has been investigated in several studies and national registries. However, the treatment has not been compared to non-surgical treatment.
View Article and Find Full Text PDFFront Public Health
September 2025
Department of Medicine, University of Chicago, Chicago, IL, United States.
Background: Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S) is a research project funded by the National Institute for Drug Abuse to implement and evaluate multi-level interventions to decrease barriers to substance use screening and treatment for PLWH. At its center is a multidomain intervention addressing digital, sociocultural, and health care system environments, at individual, interpersonal, and community levels. ePORTAL HIV-S has four overall goals; this manuscript describes the protocol specifically for the randomized control trial (RCT) portion of the study.
View Article and Find Full Text PDFJ Appl Res Intellect Disabil
September 2025
University College Dublin School of Psychology, Dublin, Ireland.
Background: Most adults with Down syndrome develop Alzheimer's disease (AD) pathology in their 30s, yet research into cognitive health programmes for this group remains limited.
Method: A mixed-methods feasibility randomised control trial (RCT) evaluated an adapted, manualised group-based cognitive stimulation therapy (CST) programme for adults with Down syndrome (N = 12; M = 30) without dementia. Participants were randomly assigned to CST (n = 6) or control (services as usual; n = 6), with assessments at baseline, post-programme, and four-month follow-up by a blinded researcher.